KRAS and non-small cell lung carcinoma: However, the emergence of sotorasib (AMG 510), an inhibitor for the treatment of NSCLC with KRAS G12C mutation, marked an initial breakthrough in KRAS mutation research and has greatly stimulated the development of KRAS inhibitors [11].